Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer
Head & Neck, 05/07/2012
Ackerstaff AH et al. – Most treatment–related quality–of–life (QOL) issues deteriorate during treatment, improve in the first year, and then remain stable, except xerostomia, improving up to the 5–year assessment point. Survivors show more positive scores for fatigue, voice, and swallowing. QOL issues at 1 year, thus, for most already represent those after 5–year follow–up.